Ovarian Cancer Clinical Trials in Maryland

Showing 221-240 of 273 trials

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

NCT01521325

This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non small cell lung cancer.

MesotheliomaPancreatic CancerOvarian Cancer+1 more

Morphotek6 participantsStarted Sep 2011

Bethesda, Maryland, United States

COMPLETEDPhase 117 miles

Immunotoxin Therapy in Treating Patients With Advanced Cancer

NCT00006981

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer. PURPOSE: Phase I trial to study the effectiveness of immunotoxins in treating patients who have advanced cancer.

Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more

National Cancer Institute (NCI)Started Dec 2000

Bethesda, Maryland, United States

COMPLETEDPhase 217 miles

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585

RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have refractory or relapsed ovarian epithelial, fallopian tube, or primary peritoneal cancer, or ovarian low malignant potential tumor.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

National Cancer Institute (NCI)Started May 2002

Bethesda, Maryland, United States • Bethesda, Maryland, United States

COMPLETEDPhase 117 miles

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

NCT00020150

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and O6-benzylguanine in treating children who have solid tumors that have not responded to previous therapy.

Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+6 more

National Cancer Institute (NCI)Started Jun 2000

Bethesda, Maryland, United States

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Ovarian Cancer Trials in Other Cities

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Other Conditions in Maryland